To investigate the persistence of infectious SARS-CoV-2 following treatment with nirmatrelvir and other protease inhibitors, emphasizing the significance of understanding viral rebound in COVID-19 patients.
Key Findings:
Infectious SARS-CoV-2 persisted in vitro after treatment with nirmatrelvir and ensitrelvir, but not with remdesivir, indicating the need for careful monitoring of treatment outcomes.
The half-life of the infectious form of SARS-CoV-2 was approximately 1 day, suggesting a potential window for viral resurgence.
Extending nirmatrelvir treatment beyond 8 days eliminated viral rebound in vitro, highlighting a possible adjustment in treatment protocols.
Interpretation:
The persistence of infectious SARS-CoV-2 following protease inhibitor therapy may contribute to viral rebound in treated patients, suggesting a need for extended treatment protocols to mitigate this risk.
Limitations:
The study was conducted in vitro and may not fully replicate in vivo conditions, necessitating caution in extrapolating results.
Further clinical trials are needed to validate the findings and treatment recommendations, ensuring they are applicable to real-world scenarios.
Conclusion:
The findings indicate a potential mechanism for SARS-CoV-2 rebound in patients treated with protease inhibitors and suggest that extending treatment duration could prevent this issue, underscoring the importance of further clinical trials.
